内源性皮质醇增多症术后缓解的心血管代谢结局:前瞻性队列研究
该前瞻性单中心队列研究(2019-2025)纳入357例内源性皮质醇增多症术后缓解的成人患者,评估术后3个月和12个月时高血压、糖尿病、高脂血症和肥胖的严重程度变化。中位12个月随访显示,库欣综合征患者高血压、糖尿病和肥胖改善率分别为70%、90%和79%,而轻度自主皮质醇分泌患者分别为51%、37%和20%;基线生化严重度评分较高与改善几率更高相关。
要点
- 库欣综合征术后高血压、糖尿病、肥胖改善率高于轻度自主皮质醇分泌患者。
- 基线生化严重度评分较高与高血压、糖尿病和肥胖改善几率增加独立相关。
- 术后应系统监测并管理心血管代谢合并症,尤其对轻度自主皮质醇分泌患者。
核心结论
- 库欣综合征和轻度自主皮质醇分泌患者术后均观察到心血管代谢合并症改善。
- 基线生化严重度评分较高与术后合并症改善几率更高相关。
研究设计与样本
- 前瞻性单中心队列研究(2019-2025年),纳入357例内源性皮质醇增多症术后缓解的成人患者。
- 患者中49%为轻度自主皮质醇分泌,36%为垂体性库欣综合征,10%为肾上腺性库欣综合征,5%为异位库欣综合征;中位年龄53岁(四分位距42-62),81%为女性。
- 基线时336例(94%)有高血压,241例(68%)有肥胖,122例(35%)有糖尿病。
主要发现
- 中位12个月随访时,库欣综合征患者高血压改善70%(90/128),轻度自主皮质醇分泌患者改善51%(60/117)。
- 库欣综合征患者糖尿病改善90%(46/51),轻度自主皮质醇分泌患者改善37%(13/35)。
- 库欣综合征患者肥胖改善79%(77/97),轻度自主皮质醇分泌患者改善20%(14/71)。
- 多变量分析显示,基线生化严重度评分较高与高血压改善(OR 1.3,95%CI 1.1-1.5)、糖尿病改善(OR 2.5,95%CI 1.7-4.1)和肥胖改善(OR 1.5,95%CI 1.2-1.8)相关。
临床怎么用
- 术后应对内源性皮质醇增多症患者系统评估和管理高血压、糖尿病、肥胖等心血管代谢合并症。
- 基线生化严重度评分较高的患者术后合并症改善可能性更大,可据此进行风险分层和随访。
局限性
- 单中心前瞻性队列设计可能限制结果的外推性。
- 部分合并症改善分析基于亚组患者,样本量有限。
- 随访中位时间为12个月,长期结局未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Evidence on the evolution of cardiometabolic comorbidities following surgical remission of hypercortisolism is scarce. OBJECTIVE: To determine the impact of surgical remission on cardiometabolic comorbidities in patients with endogenous hypercortisolism and to identify factors associated with cardiometabolic improvement. METHODS: Prospective single-center cohort study (2019-2025) of adults with Cushing syndrome (CS) or mild autonomous cortisol secretion (MACS) with surgical remission of hypercortisolism. Outcomes included (1) changes in severity of hypertension, diabetes mellitus (DM), hyperlipidemia, and obesity between baseline, 3, and 12 months postremission and (2) factors associated with improvement in comorbidities. RESULTS: Among 357 patients (49% MACS, 36% pituitary CS, 10% adrenal CS, 5% ectopic CS; median age 53 years [interquartile range 42-62]; 81% women), 336 (94%) had hypertension, 241 (68%) had obesity, and 122 (35%) had DM. At a median of 12 months postsurgery, improvement in hypertension occurred in 70% (90/128) of patients with CS and 51% (60/117) of patients with MACS, DM in 90% (46/51) patients with CS and 37% (13/35) patients with MACS, and obesity in 79% (77/97) patients with CS and 20% (14/71) patients with MACS. In a multivariable analysis, higher baseline biochemical severity scores were associated with improvement in hypertension [odds ratio (OR) 1.3, 95% confidence interval (CI) 1.1-1.5), DM (OR 2.5, 95% CI 1.7-4.1), and obesity (OR 1.5, 95% CI 1.2-1.8) at a median of 12 months postremission of hypercortisolism. CONCLUSION: Postsurgical improvement of cardiometabolic comorbidities was observed in both patients with CS and MACS. Higher baseline biochemical severity scores were associated with higher postremission improvement in comorbidities.
引用
- Chacko SR, Sharma SS, Ahmadian S, et al. Cardiometabolic Outcomes after Surgical Remission of Endogenous Hypercortisolism: A Prospective Cohort Study. J Clin Endocrinol Metab. 2026. PMID: 41466357. doi:10.1210/clinem/dgaf693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。